Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Psoriasis and Pruritus Trial of SNA-120

Trial Profile

A Phase III Psoriasis and Pruritus Trial of SNA-120

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcantratinib (Primary)
  • Indications Pruritus; Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 05 Aug 2019 According to a Sienna Biopharmaceuticals media release, the company will continue to explore capital raising to enable the initiation of the planned Phase 3 pivotal clinical trials for SNA-120 (pegcantratinib; CT profile 232992 and 305470), in addition to exploring a wide range of financial and strategic alternatives.The company does not intend to initiate these planned phase 3 trials of SNA-120 until the company secures sufficient additional capital.
    • 14 Mar 2019 According to a Sienna Biopharmaceuticals media release, following an end-of-phase 2 (EOP2) meeting with FDA scheduled for April 2019, the company plans to initiate this trial for a psoriasis indication, subject to securing sufficient capital to complete this trial, in the second half of 2019.
    • 03 Dec 2018 According to a Sienna Biopharmaceuticals media release, the company expect to start this phase 3 study for psoriasis in the second half of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top